Literature DB >> 3711481

Importance of continued activation of thrombin reflected by fibrinopeptide A to the efficacy of thrombolysis.

P R Eisenberg, L Sherman, M Rich, D Schwartz, K Schechtman, E M Geltman, B E Sobel, A S Jaffe.   

Abstract

Factors responsible for initial success or failure of coronary thrombolysis and persistent recanalization or early reocclusion have not been thoroughly elucidated. Both adequate initial clot lysis and preclusion of rethrombosis are required. Failure may reflect clot lysis followed immediately or somewhat later by rethrombosis. To determine whether differences in the intensity and persistence of the activation of thrombin are determinants of success or failure of recanalization, plasma fibrinopeptide A, a fibrinogen product liberated by thrombin, was serially assayed in 19 patients treated with intravenous streptokinase. In patients exhibiting recanalization (n = 9), plasma fibrinopeptide A decreased after administration of streptokinase but before administration of heparin. In patients without initially apparent recanalization, fibrinopeptide A increased, suggesting ongoing thrombosis, and subsequently decreased promptly after heparin. In patients with initial recanalization followed by overt reocclusion the pattern was different. Despite recanalization, fibrinopeptide A continued to rise markedly. Elevations persisted despite administration of heparin. Thus, inhibition of activation of thrombin is associated with successful recanalization. Conversely, persistent activation of thrombin may be a predisposing factor to both apparent initial failure of recanalization and overt early reocclusion.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3711481     DOI: 10.1016/s0735-1097(86)80144-9

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  11 in total

Review 1.  Advances in thrombolytic therapy.

Authors:  M Verstraete
Journal:  Cardiovasc Drugs Ther       Date:  1992-04       Impact factor: 3.727

Review 2.  Intravenous streptokinase. A reappraisal of its therapeutic use in acute myocardial infarction.

Authors:  K L Goa; J M Henwood; J F Stolz; M S Langley; S P Clissold
Journal:  Drugs       Date:  1990-05       Impact factor: 9.546

3.  Antithrombotic efficacy of a novel factor Xa inhibitor, FXV673, in a canine model of coronary artery thrombolysis.

Authors:  S S Rebello; R G Bentley; S R Morgan; C J Kasiewski; V Chu; M H Perrone; R J Leadley
Journal:  Br J Pharmacol       Date:  2001-08       Impact factor: 8.739

4.  The Association of Anticoagulant Protein Concentrations with Acute Myocardial Infarction in the Thromholysis in Myocardial Infarction Phase II (TIMI II) Trial.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1998       Impact factor: 2.300

5.  Improving the Efficacy and Stability of Coronary Reperfusion Following Thrombolysis: Exploring the Thrombin Hypothesis.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1995       Impact factor: 2.300

6.  Novel Antithrombotic Strategies for the Treatment of Coronary Artery Thrombosis: A Critical Appraisal.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1995       Impact factor: 2.300

7.  Surface 12-Lead Electrocardiographic Findings and Plasma Markers of Thrombin Activity and Generation in Patients with Myocardial Ischemia at Rest.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1994       Impact factor: 2.300

8.  Thrombin: Structure, Biochemistry, Measurement, and Status in Clinical Medicine.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1998-07       Impact factor: 2.300

9.  Human tissue-type plasminogen activator releases fibrinopeptides A and B from fibrinogen.

Authors:  J I Weitz; M K Cruickshank; B Thong; B Leslie; M N Levine; J Ginsberg; T Eckhardt
Journal:  J Clin Invest       Date:  1988-11       Impact factor: 14.808

Review 10.  Streptokinase. A review of its pharmacology and therapeutic efficacy in acute myocardial infarction in older patients.

Authors:  P E Battershill; P Benfield; K L Goa
Journal:  Drugs Aging       Date:  1994-01       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.